Imunon
Open
$2.73
Prev. Close
$2.73
High
$2.79
Low
$2.73
Market Snapshot
$8.23M
-0.6
-22.70
25
Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
emptyResult
Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Recently from Cashu
Title: "Imunon: Key Developments and Future Prospects in Biotechnology Sector
Please provide the text you would like me to summarize into a 300-word article.
Imunon: A Brief Overview of Company Developments and Stock Performance
Please provide the text you would like me to summarize into an article.
Imunon Expands Therapeutic Pipeline Amid Competitive Biopharmaceutical Industry Developments
Imunon Takes Steps Toward Expanding Therapeutic Pipeline Amidst Industry Developments Imunon, a biopharmaceutical company specializing in developing innovative therapies for various cancers and infect…
Imunon and Earnings Reports Highlight Corporate Resilience Across Diverse Sectors
Earnings Reports Shine Light on Corporate Resilience in Diverse Sectors In a notable development, the recent wave of earnings reports from various companies highlights the resilience and adaptability…